Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors during the central anxious program, conolidine modulates alternate molecular targets. A Science Advances study found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://michaelv751jbj0.wikibriefing.com/user